Published in J Neurol Neurosurg Psychiatry on June 01, 2006
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis. J Clin Cell Immunol (2013) 0.89
Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Arch Neurol (2010) 0.86
Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage. PLoS One (2009) 0.86
Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. Mult Scler (2013) 0.80
Anti-myelin antibodies in multiple sclerosis: clinically useful? J Neurol Neurosurg Psychiatry (2006) 0.75
Methodological Challenges in Protein Microarray and Immunohistochemistry for the Discovery of Novel Autoantibodies in Paediatric Acute Disseminated Encephalomyelitis. Int J Mol Sci (2017) 0.75
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem (1987) 59.79
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Multiple sclerosis. N Engl J Med (2000) 12.69
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol (2000) 9.73
Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem (1972) 4.87
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med (2003) 4.86
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med (2002) 3.74
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med (2001) 2.27
A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol (1984) 2.09
The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol (2000) 2.07
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology (1988) 2.03
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta (1987) 1.88
Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol (1998) 1.56
Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol (1997) 1.55
Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler (2005) 1.11
Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol (1999) 1.06
Antibody response to myelin oligodendrocyte glycoprotein and myelin basic protein depend on familial background and are partially associated with human leukocyte antigen alleles in multiplex families and sporadic multiple sclerosis. J Neuroimmunol (2002) 0.81
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 2.96
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler (2012) 1.73
Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology (2008) 1.62
Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler (2007) 1.49
A comparative study of the relative bioavailability of different interferon beta preparations. Neurology (2000) 1.45
Real-time sonoelastography: findings in patients with symptomatic achilles tendons and comparison to healthy volunteers. Ultraschall Med (2009) 1.23
Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler (2008) 1.19
Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology (1999) 1.11
Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler (2005) 1.11
The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J Neuroimmunol (2001) 1.03
Expression of Fas and Fas ligand after experimental traumatic brain injury in the rat. J Cereb Blood Flow Metab (2000) 1.00
Targeting the Nogo receptor complex in diseases of the central nervous system. Curr Med Chem (2011) 0.93
Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology (2001) 0.93
The thymus and self-tolerance: co-existence of encephalitogenic S100 beta-specific T cells and their nominal autoantigen in the normal adult rat thymus. Int Immunol (1997) 0.92
Increased expression of apolipoprotein D following experimental traumatic brain injury. J Neurochem (1999) 0.91
Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res (2001) 0.91
Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler (2001) 0.88
Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b. J Interferon Cytokine Res (2001) 0.87
Olfactory threshold is impaired in early, active multiple sclerosis. Mult Scler (2011) 0.87
A critical comparison of frequently used methods for the analysis of tumor necrosis factor-alpha expression by human immune cells. J Immunol Methods (2000) 0.83
Proposal for modification of the TNM staging classification for cancer of the oral cavity. DOSAK. J Craniomaxillofac Surg (1999) 0.83
High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study. Mult Scler (2009) 0.83
Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler (2007) 0.83
Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler (2004) 0.82
Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis. J Neural Transm Suppl (2000) 0.79
Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler (2006) 0.78
Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler (2004) 0.78
Comparative study of four different assays for the detection of binding antibodies against interferon-beta. Mult Scler (2008) 0.78
Monoclonal antibodies in the treatment of multiple sclerosis. Curr Med Chem (2009) 0.77
Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies. J Neuroimmunol (2006) 0.77
Genetic variants in the tumor necrosis factor receptor II gene in patients with multiple sclerosis. Tissue Antigens (2004) 0.77
Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event. Eur J Neurol (2007) 0.77
Fine mapping of T-cell immunoglobulin mucin domain gene 1 failed to detect a significant association with multiple sclerosis. Tissue Antigens (2010) 0.76
A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta. Mult Scler (2003) 0.76
Ultrastructure of alpha-synuclein-positive aggregations in U373 astrocytoma and rat primary glial cells. Neurosci Lett (2002) 0.76
Development of a mirror-based endoscope for divertor spectroscopy on JET with the new ITER-like wall (invited). Rev Sci Instrum (2012) 0.75
Eligibility as a foundation for rehabilitation casework. J Rehabil (1980) 0.75
[Microsurgical erbium YAG system for use in ophthalmology]. Biomed Tech (Berl) (1997) 0.75
Diffuse laser light reflection from the surfaces of surgical instruments. Biomed Tech (Berl) (1987) 0.75
[Treatment of the combined pelvic and thoracic trauma in the emergency room]. Unfallchirurg (2006) 0.75
Are cytokines and adhesion molecules useful parameters to differentiate bacterial from fungal ventriculitis? Intensive Care Med (2001) 0.75